BACKGROUND: Over a century of advancements in the field of additive solutions for red blood cell (RBC) storage has made transfusion therapy a safe and effective practice for millions of recipients worldwide. Still, storage in the blood bank results in the progressive accumulation of metabolic alterations, a phenomenon that is mitigated by storage in novel storage additives, such as alkaline additive solutions. While novel alkaline additive formulations have been proposed, no metabolomics characterization has been performed to date.
RESULTS:
Alkaline additives (especially PAG3M) better preserved 2,3-diphosphoglycerate and adenosine triphosphate (ATP). Deaminated purines such as hypoxanthine were predictive of hemolysis and morphological alterations. Guanosine supplementation in PAGGSM and PAG3M fueled ATP generation by feeding into the nonoxidative pentose phosphate pathway via phosphoribolysis. Decreased urate to hypoxanthine ratios were observed in alkaline additives, suggestive of decreased generation of urate and hydrogen peroxide. Despite the many benefits observed in purine and redox metabolism, alkaline additives did not prevent accumulation of free fatty acids and oxidized byproducts, opening a window for future alkaline formulations including (lipophilic) antioxidants.
CONCLUSION: Alkalinization via different strategies
(replacement of chloride anions with either high bicarbonate, high citrate/phosphate, or membrane impermeant gluconate) results in different metabolic outcomes, which are superior to current canonical additives in all cases.
O ne hundred years of advancements in the field of transfusion medicine and, in particular, storage additives for red blood cells (RBCs) [1] [2] [3] have made transfusion therapy a safe and effective mainstay of current medical practice for over 11 million Americans every year. 4 In 1981 the first modernera additive containing saline, adenine, glucose, and mannitol (SAGM) was formulated. This allowed storage of RBCs for up to 6 weeks owing to the role of mannitol in balancing osmolarity and decreasing hemolysis. 5 A similar additive solution (AS-1) to SAGM was subsequently formulated in the United States. 6 AS-3 and AS-5 [6] [7] [8] were designed in the subsequent decades, with AS-3 containing phosphate buffers and citrate (instead of mannitol) to fuel synthesis of high-energy phosphate compounds and make this additive more viable to pediatric patients, respectively. Over the years, SAGM modifications have been formulated, including guanosine as a source of ribose phosphate secondary to phosphoribolysis (PAGGSM), which thus sustains late adenosine triphosphate (ATP)-generating glycolysis reactions without the need for a net expenditure of ATP. 9 More recently, novel additives such as AS-7 (commercial name SOLX) 10 or erythrosol-5 (E-SOL 5) 11 were designed building on the concept of chloride shift [12] [13] [14] -which favors intracellular pH alkalinization by promoting chloride efflux in low-chloride/chloride-free/ high-bicarbonate additives-with beneficial effects to energy and redox metabolism (reviewed here). 15 Similar effects could be obtained by replacing the saline component with salt-containing membrane-impermeant anions such as sodium gluconate, which generates a reversible intracellular alkalosis.
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With over 112.5 million units donated globally every year and an average end-of-storage loss of potency of at least approximately 17% 19 in current additives (calculated from posttransfusion recovery studies), 20 novel storage additives still offer an actionable window of opportunity to significantly impact the field of transfusion medicine by improving RBC storage quality. 21 Alterations of purine metabolism resulting from ATP consumption and breakdown into purines like hypoxanthine are markers of the metabolic age of RBCs. 22 Decreases in the levels of nondeaminated purines cannot be corrected by additional adenine loading of storage additives. 23 Activation of purine deaminases such as erythrocyte-specific adenosine monophosphate (AMP) deaminase 3 in turn results in potentially toxic by-products such as hypoxanthine. Hypoxanthine has been recently identified as a negative predictor of posttransfusion recovery in stored mouse and human RBCs 24 and a substrate for circulating xanthine oxidase for the generation of urate and hydrogen peroxide. 25 In this view, end-of-storage rejuvenation of RBCs has been proposed, which exploits inosine and pyruvate to replenish late glycolysis via phosphoribolysis-derived pentose phosphate sugars and to promote oxidation of NADH back to NAD1 via lactate dehydrogenase, respectively. However, excess inosine transformation to hypoxanthine results in the necessity to wash rejuvenated units prior to transfusion. 26 In addition, the use of alternative sugars (or sugar alcohols) instead of glucose, such as mannose, fructose, or sorbitol (as a replacement for mannitol) 27, 28 has been proposed as a viable strategy to bypass early glycolytic blockade promoted by feedback inhibition of phosphofructokinase by intracellular acidification, a mechanism evolutionarily exploited by animals such as naked molerats to resist extreme anoxia. 29 Finally, antioxidants such as vitamin C, N-acetylcysteine, and vitamin E have been proposed as additives for RBC storage in that they attenuate the oxidative storage lesion, especially to the lipid component, [30] [31] [32] [33] [34] which is relevant in the light of the correlation between lipid oxidation and posttransfusion recovery. 35 The current availability of new "omics" technologies is providing increased understanding of the RBC proteome and metabolome. 36, 37 For example, although RBCs lack mitochondria, they have now been shown to metabolize carboxylic acids from citrated anticoagulants or storage additives 38, 39 in an oxygen-dependent fashion. 40 Omics technologies have helped investigators in the field of transfusion medicine to characterize the multifaceted nature of the storage lesion 41 and, by qualitatively and quantitatively characterizing its evolution in different storage additives, [42] [43] [44] [45] pave the way for future developments in the field. Recently, we performed a comparative analysis of hemolysis, ion homeostasis, and osmotic fragility of RBCs stored in five different additives. 46 Here, we expand on those observations by providing metabolomics evidence of the beneficial effects of alkaline additives when compared to AS-3 and correlating metabolomics data to previously measured functional parameters.
MATERIALS AND METHODS
Commercial reagents were purchased from Sigma-Aldrich unless otherwise noted.
Blood collection, processing, and storage
Blood collection, processing, and storage were described in detail elsewhere. 46 Briefly, 500 mL blood in citrate- 46 Here, we wanted to test whether these observations for 2,3-diphosphoglycerate (DPG) could be also expanded to other metabolic pathways. RBCs and supernatants were separated by centrifugation at 2000 3 g for 10 minutes at 48C at each time point, and the RBC pellets were shipped frozen to the metabolomics facility to be processed for metabolomics analyses as described below.
Osmotic fragility, morphology, and gas measurements were performed as previously reported. 46 
Metabolite extraction
A volume of 50 mL of RBCs was extracted in 450 mL of lysis buffer (methanol:acetonitrile:water 5:3:2), before ice cold extraction by vortexing for 30 minutes at 48C. 15, 38 Insoluble proteins were pelleted by centrifugation (10 minutes at 48C and 10,000 3 g) and supernatants were collected and stored at 2808C until analysis.
UHPLC-MS metabolomics
Analyses were performed using a liquid chromatograpy system (Vanquish UHPLC, Thermo Fisher) coupled online to a mass spectrometer (Q Exactive, Thermo Fisher). Samples were resolved over a core-shell column (2.1 3 150 mm, 1.7 mm; Kinetex C18, Phenomenex) at 258C using a 3-minute isocratic condition of 5% acetonitrile, 95% water, and 0.1% formic acid flowing at 250 mL/min, 47 or using a 9-minute gradient at 400 mL/min from 5% to 95% B (A: water/0.1% formic acid; B: acetonitrile/0.1% formic acid). 38 Mass spectrometry analysis and data elaboration were performed as described. 38 Metabolite assignments were performed using computer software (MAVEN, Princeton University), as described. 48 
Statistical analyses
Graphs and statistical analyses, including partial least square-discriminant analysis (PLS-DA) and two-factor (time series 1 one-factor) statistical analysis were performed with computer software (GraphPad Prism 5.0, GraphPad Software, Inc.) and Metaboanalyst 3.0. 49 Line plots were performed through interpolation of available data points for all tested storage days (third-degree polynomials) via GraphPad Prism. Metabolic linkage analyses have been recently described. 50 Briefly, correlative analyses (Pearson or Spearman correlations-r-upon testing for normality distribution of data with Kolmogorov-Smirnov) and calculation of D|r|>30% deviations were performed with GraphPad Prism 5.0 and Excel 2017 (Microsoft), while results were plotted with computer software (GENE-E, Broad Institute). Briefly, the underlying assumption of the metabolic linkage analysis 50 is that even though correlation does not necessarily imply causation, the levels of metabolites from linked pathways are highly correlated owing to biochemical constraints of the enzymatic reactions necessary to consume one metabolite to generate another.
RESULTS
Gas and ion homeostasis, osmotic fragility, phosphatidylserine exposure, and morphology
Hematocrit, mean cell volume (MCV), pH, % hemolysis, osmotic fragility, phosphatidylserine (PS) exposure and morphologic alterations (reported as percentage of echinocytes) were measured for RBCs stored in different additives (in part previously reported 46 and here reelaborated in
Figs. S1 and S2, available as supporting information in the online version of this paper). Though limited by the lack of functional in vivo measurements of RBC storage quality and transfusion efficacy (e.g., posttransfusion recoveries), the parameters we measured here represent important surrogate indexes of "functional" relevance (e.g., percentage of spontaneous and osmotic hemolysis). Mean cell volume was highest in SAGM RBCs throughout storage (Fig. S2) . SAGM RBCs had the highest end-of-storage osmotic fragility, with trends toward increase during storage duration (consistent with previous observations), 51 while other additives showed trends toward decrease (Fig. S1 ). Alkalinization in the various additives was achieved either by high bicarbonate load (SOLX), low chloride (PAGGSM), or no chloride (PA3GM, SOLX and E-SOL 5; Fig. S2 ). Lower endof-storage pH was observed in PAG3M and PAGGSM in comparison to SOLX and E-SOL 5, though trends were mostly comparable across all additives. E-SOL 5 and PAG3M showed the lowest end-of-storage hemolysis and highest-though within a very narrow window range-PS exposure (the latter parameter normalized across additives by incubation at 378C), despite all additives showing a similar percentage of echinocytes upon morphologic analysis throughout storage (Fig. S1 ).
Metabolomics overview
Metabolomics analyses were performed at Days 1, 21, 35 (end of standard storage in the Netherlands), and 56.
Results are extensively reported in Table S1 , available as supporting information in the online version of this paper. Hierarchical clustering of metabolic trends in all additives was performed (Fig. S3 , available as supporting information in the online version of this paper) and a detail of the top significant features (repeated measures ANOVA; p < 0.01 false discovery rate corrected) is reported in Fig. 1 . On the basis of these metabolic phenotypes, we clustered samples via PLS-DA ( Fig. 2A ; two-dimensional plots for PC1 vs. PC2, PC1 vs. PC3, and PC2 vs. PC3 are reported in Fig. S4 [available as supporting information in the online version of this paper]), showing that PAG3M was the only additive not showing the typical U-shaped progression over PC1 and PC2 previously described by us and others. 22, 43 Notably, glycolytic measurements through classic spectrophotometric approaches and UHPLC-MS ( Fig. 2B and C, respectively) concordantly showed higher glucose consumption and generation of ATP, DPG, and lactate in PAG3M, which contained half the initial dose of glucose as SOLX and E-SOL 5.
In particular, despite the lower intracellular pH, PAG3M better preserved DPG levels throughout storage, followed by SOLX and E-SOL 5 (Fig. 2B) . No significant alterations in reduced to oxidized glutathione ratios (glutathione/ glutathione disulfide [GSSG]) were observed across additives, though PAG3M showed the highest sedoheptulose phosphate/6-phosphogluconate ratio and E-SOL 5 the lowest (Fig. 2C ). In the absence of flux data, this observation is suggestive of increased fluxes through the pentose phosphate pathway (PPP) in PAG3M-stored RBCs, suggestive of higher NADPH-generating (i.e., oxidized thiol-reducing) capacity. E-SOL 5 and SOLX had the highest levels of intracellular malate (declining in all additives over storage, likely owing to release in the supernatants), despite higher levels of citrate in the former additive (Fig. 2D) . Metabolic linkage analysis ( Fig. 3 ; extensively described in previous reports) 50 allows the determination of metabolic reprogramming of RBCs stored in different additives. The underlying rationale for this approach is that biochemical constraints of enzymatic reactions result in strong and significant positive/negative correlations across metabolites in the same pathways, unless the activity of one enzyme in the cascade is up/down regulated by modulatory events (e.g., inactivating oxidation of active site cysteine of glyceraldehyde 3-phosphate dehydrogenase is observed during RBC storage). 53 Metabolite levels in SAGM RBCs were correlated to each other, prior to repeating a similar correlation analysis across all additives while maintaining the order of metabolites of original elaborations in SAGM (Fig. 3A) or performing a hierarchical clustering of correlations in an additive-by-additive fashion (Fig. 3B ). This analysis provides at a glance an overview of metabolic rewiring across additives, indicating a strong effect on redox homeostasis, carboxylic acid, fatty acid, and purine metabolism in alkaline additives when compared to SAGM ( Fig. 3 ; Supplementary Table 2 ). Of note, changes in glutamine metabolism and glutathione homeostasis were observed across additives with respect to total glutathione levels (both reduced and oxidized being lowest in PAGGSM; Fig. S5 [available as supporting information in the online version of this paper]). SAGM showed the highest levels of GSSG for the first 21 days of storage. Cysteine accumulated significantly in E-SOL 5 RBCs over storage duration in comparison to other additives, mainly at outdate of the unit at Storage Day 56 (Fig. S6 , available as supporting information in the online version of this paper).
Purine and fatty acid metabolism
Supplementation of guanosine in PAGGSM and PAG3M resulted in significantly higher levels of guanine and adenosine and comparably lower levels of inosine (especially PAG3M) in comparison to all the other additives tested here (Fig. 4) . This is suggestive of guanosine from PAGGSM and PAG3M being mostly metabolized via phosphoribolysis rather than hypoxanthine guanosine phosphoribosyl transferase (HGPRT). Deaminated purines (and the ratio of deaminated/nondeaminated purines-e.g., adenosine/inosine; AMP/inosine monophosphate; adenine/hypoxanthine) were the lowest in PAG3M (Fig. 4) . On the other hand, urate to xanthine (or hypoxanthine) ratios were the highest in E-SOL 5 and SAGM, followed by SOLX (Fig. 4) . Inferring from steadystate data, these results are suggestive of increased purine deamination and catabolism to urate (a reaction that also generates the pro-oxidant hydrogen peroxide) in SAGM and E-SOL 5, in part mitigated by SOLX. On the other hand, SOLX showed the lowest accumulation of free fatty acids and arachidonic acid peroxidation products, followed by SAGM, PAGGSM, E-SOL 5 and PAG3M (Fig. S3) .
Correlation of metabolomics data to functional outcomes
Metabolomics data were correlated to functional outcomes (including energy state as determined by ATP levels, hemolysis, osmotic fragility, PS exposure and morphological alterations) in additive-dependent (Table  S1 , Figs. 5 and 6B) and an additive independent fashion (Fig. S7 [available as supporting information in the online version of this paper], Fig. 6A ). An overview of top metabolites showing significant positive (red) or negative (blue) correlations to ATP across all additives is provided in Fig.  5A . Of note, most trends observed showed a progression towards increasingly higher (e.g., lactate and ATP; Fig. 5B ) or lower (e.g. ATP and sphingosine 1-phosphate) correlations across all additives (Fig. 5A) . Correlations between ATP and DPG were poor for all additives except for PAG3M (Fig. 5C) , suggesting a rewiring of the RapoportLuebering shunt specific to this additive. Of note, purine metabolites (especially ATP, adenosine, and the deamination products inosine and hyopoxanthine) were the best correlates with functional outcomes (Fig. 6B) , with hypoxanthine being the best predictor of hemolysis and morphological alterations (percentage of echinocytes) in all additives. Of note, inosine was a good predictor of osmotic fragility in all additives except for SAGM (Fig. 6B) .
DISCUSSION
In the past few years, metabolomics analyses of stored RBCs have generated a wealth of observational data whose clinical relevance is still matter of debate. 54 Based on the consideration that, in order to transport and deliver oxygen, transfused RBCs must remain intact and circulate in the bloodstream of the recipient, correlative studies have been published in mice and humans suggesting a role for lipid and purine oxidation (e.g., 5-hydroxyeisosatetraenoic acid and other hydroxyeisosatetraenoic acids, ATP, and hypoxanthine) in mediating RBC hemolysis and posttransfusion recovery. 24, 35, 55, 56 These observations are relevant in that In the present study, we generated metabolomics data on five storage additives, including SAGM, the canonical European storage solution, and more recently introduced PAGGSM, as well as three alkaline additives (SOLX, E-SOL 5, and PAG3M). Of note, results on SAGM and PAGGSM we report here are consistent with findings reported by Rolfsson and colleagues, 39 who also explored the metabolic impact of other nonalkaline additives such as AS-1 and AS-3, but did not focus on the impact of intracellular alkalinization on stored erythrocyte metabolism. Intracellular alkalinization is achieved in these additives by exploiting the chloride shift concept, by eliminating chloride anions from the formulation balanced by either high bicarbonate loading (SOLX), high citrate and phosphate (E-SOL 5), or membrane-impermeant gluconate (PAG3M). Theoretically, the chloride-efflux effect induced by incorporation of gluconate in the additive should be reversible once anionic equilibrium is reached, unlike the chloride efflux induced by low/no-chloride highbicarbonate additives. However, the chloride shift impact of gluconate (as determined by measurements of bicarbonate and chloride anions; Fig. S2 ) perfectly overlaps in the alkaline additives PAG3M, E-SOL 5, and SOLX. Still, the gluconate-containing additive (PAG3M) showed the highest DPG levels through the whole storage period, suggesting that phenomena other than alkalinization alone (i.e., fueling of late glycolysis by pentose phosphate compounds released via phosphoribolysis of guanosine) may contribute to the beneficial activation of the Rapoport-Luebering shunt. Classic biochemical understanding of RBC energy metabolism posits that the synthesis of 2,3-DPG through the Rapoport-Luebering shunt "sacrifices" the generation of one molecule of ATP. 57 While this held true also in the present study for all storage additives, including alkaline-and guanosine-containing additives, gluconate-containing PAG3M was the only additive showing significant positive correlations between the levels of ATP and 2,3-DPG, highlighting a metabolic peculiarity of RBCs stored in presence of the PAG3M formula. Intracellular alkalinization is anticipated to boost glycolysis, the PPP, and the Rapoport-Luebering pathway through the pH-dependent increases in the activity of the rate-limiting enzymes phosphofructokinase, glucose-6-phosphate dehydrogenase, and bisphosphoglycerate mutase. 15 Here, we show that decreased RBC spiculation (i.e., formation of morphologically altered echinocytes) and hemolysis are observed in alkaline additives, a phenomenon that correlated with reduced ATP breakdown and purine deamination rather than free fatty acids and fatty acid oxidation. This observation, while preliminary, is suggestive of the fact that preserved energy homeostasis mitigates RBC spiculation, a "save or sacrifice" phenomenon to eliminate oxidation products (including oxidized lipids). However, preserved energy homeostasis in alkaline additives (especially PAG3M and E-SOL 5) is not sufficient to completely prevent lipid oxidation, for which introduction of hydrophilic (e.g., ascorbate) or lipophilic (e.g., vitamin E) antioxidants may represent a better option. [30] [31] [32] [33] [34] An alternative explanation to this phenomenon is an increase in oxidized lipid recycling through the Lands cycle, a phenomenon that is promoted by hypoxia 58 and may be similarly affected by alkalinization.
On the other hand, alkaline additives effectively prevented purine deamination, especially in the case of PAG3M. Of note, introduction of guanosine to the additive formulation of PAGGSM and PAG3M ended up boosting the guanine nucleotide pool and fueling ATP generation with no initial energy investment in late glycolysis via phosphoribolysis, rather than generation of inosine through the activity of hypoxanthine guanosine phosphoribosyl transferase. Lower levels of hypoxanthine and higher ratios of nondeaminated to deaminated purines (e.g., ATP/hypoxanthine) or decreased purine oxidation catabolites (urate/hypoxanthine) were indeed observed in all alkaline additives, especially in PAG3M, SOLX, and E-SOL 5 (in that order).
Increased phosphoribolysis may also explain the observed increases in steady-state levels of nonoxidative-phase PPP metabolites (e.g., sedoheptulose phosphate). This observation could also be alternatively explained by increased fluxes through the oxidative PPP, resulting in higher nonoxidative/oxidative PPP intermediate ratios (consistent with higher glucose-6-phosphate dehydrogenase activity and thus increased antioxidant capacity in alkaline RBCs). Indeed, we recently appreciated the role that oxidative stress plays in activating AMP deaminase 3 to promote purine deamination and thus hypoxanthine accumulation, a phenomenon that negatively correlates with posttransfusion recovery and is prevented by hypoxic storage (which also induces intracellular alkalinization). 24 However, direct comparison of hypoxanthine levels in alkaline versus nonalkaline additives (SOLX vs. AS-3) in unpaired studies showed increases in the former group, also accompanied by higher total levels of nondeaminated purines and ATP. 45 Similarly, supplementation of CO 2 to hypoxically stored RBCs decreased hypoxanthine levels but increased urate/hypoxanthine ratios. This suggests a role of alkalinization in preventing hypoxanthine catabolism or a phenomenon independent from alkalinization in explaining hypoxia-induced decreases in RBC hypoxanthine. 57 Similarly, it must be noted that, unlike RBCs, mitochondria-endowed cells generate hypoxanthine under hypoxic conditions, a caveat that would recommend caution when considering purine deaminationrelated data on hypoxic storage of RBCs in the presence of residual WBCs (while the leukoreduced RBC units used for this study have <0.1 3 10 6 WBCs). Alternatively, ATP/hypoxanthine ratios, or hypoxanthine metabolism to urate and hydrogen peroxide, rather than hypoxanthine levels per se, may be candidate markers of the RBC metabolic lesion for future studies. Finally, activation of Future additives may contain antioxidants to promote energy metabolism via inhibition of purine deamination by redox-sensitive deaminases, although antioxidants other than ascorbates or sugars other than glucose should be included in those formulations to avoid the negative effect on glycolysis triggered by competitive uptake of glucose and dehydroascorbate by glucose transporter 1.
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CONCLUSION
In the present study, we provided the first comparative metabolomics analysis of RBCs stored in different alkaline additives SOLX, E-SOL 5, and PAG3M or in nonalkaline/ classic additives such as SAGM or PAGGSM. The results from our metabolic analyses indicate superior RBC preservation in PAG3M as compared to the other alkaline additives and, in general, in alkaline additives as compared to nonalkaline SAGM and PAGGSM. In particular, DPG and ATP generation and maintenance, as well as purine metabolism and redox homeostasis (especially the PPP and its nonoxidative-phase by-products) were favorable in PAG3M and other alkaline additives in comparison to SAGM and PAGGSM. However, the observed metabolic benefits do not extend to the prevention of storageinduced fatty acid release and lipid oxidation. The correlation of metabolites from these pathways with surrogate ex vivo indexes of functional outcomes (e.g., cell morphology and osmotic fragility) are relevant in that they confirm and extend the recent observation on the (correlative) role of purine deamination in RBC recovery after transfusion. 24 However, additional functional in vivo measurements (e.g., posttransfusion recovery) will be instrumental to further expand our understanding of the impact of these storage additives on transfusion efficacy. Results from the present study provide additional insights in the metabolic benefits of alkaline storage additives and will likely guide the formulation of novel additives in the near future.
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